The FDA has cleared Magstim, a company based in Wales, to introduce its intermittent Theta Burst Stimulation (iTBS) as a treatment for Major Depressive Disorder. The therapy is available on the company’s Horizon transcranial magnetic stimulation (TMS) systems and only takes about three minutes per session.

Previously, so-called repetitive transcranial magnetic stimulation (rTMS) using the Horizon would take up to 38 minutes to complete, and even accelerated TMS would require 19 minutes. This is certainly a major benefit to patients and providers, as patients don’t have to put up with unpleasantly long treatment times and clinicians can have a higher throughput.

Discover The World's MOST COMPREHENSIVE Mental Health Assessment Platform

Efficiently assess your patients for 80+ possible conditions with a single dynamic, intuitive mental health assessment. As low as $12 per patient per year.

The Horizon features Magstim’s proprietary Energy Recovery System that makes sure that the magnetic pulse delivered is consistent throughout each cycle. This helps to guarantee consistent dosing and get closer to predictable results.

The new offering does not require any hardware or software upgrades from existing users, allowing it to be introduced immediately.

“I am pleased that we can now market the full capabilities of the Horizon Performance platform,” said Lothar Krinke, CEO of Magstim, in a statement. “The versatility coupled with the proprietary Energy Recovery System gives us a distinct advantage in the market. We want to provide innovative systems that allow clinicians and researchers to customize and personalize treatment for patients, and this clearance is another step in that direction.”

Hot daily news right into your inbox.